Elizabeth Buck
Founder at BLACK DIAMOND THERAPEUTICS, INC.
Net worth: 482 623 $ as of 2024-03-30
Network origin in Elizabeth Buck first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Public Company | Biotechnology | 24 | |
| Public Company | Electrical Products | 5 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Elizabeth Buck via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Sales & Marketing Corporate Officer/Principal | |
| ELI LILLY AND COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| ROCHE HOLDING AG | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
BioVex, Inc.
 BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Pharmaceuticals: Major | Director/Board Member | |
| GENOCEA BIOSCIENCES, INC. | Biotechnology | Director/Board Member | |
| RA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Investor Relations Contact | |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | College/University | Doctorate Degree Doctorate Degree | |
Bain & Co., Inc.
 Bain & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Bain & Co., Inc. provides management consulting services. It offers advisory services to the companies on their critical issues and opportunities: strategy, marketing, organization, operations, technology and mergers and acquisitions, across all industries and geographies. The company was founded in 1973 and is headquartered in Boston, MA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| Imperial College London | College/University | Undergraduate Degree Undergraduate Degree | |
| University of Cambridge | College/University | Doctorate Degree Doctorate Degree | |
Morgan Stanley Venture Partners
 Morgan Stanley Venture Partners Investment ManagersFinance Morgan Stanley Venture Partners (MSVP) is a venture capital firm subsidiary of Morgan Stanley Investment Management Merchant Banking, which is ultimately owned by Morgan Stanley (NYSE: MWD) founded in 1986.The firm is headquartered in New York. | Investment Managers | Private Equity Analyst | |
| University of Toronto | College/University | Undergraduate Degree Doctorate Degree | |
Versant Venture Management LLC
 Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Investment Managers | Chairman Corporate Officer/Principal | |
Amgen Rockville, Inc.
 Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Biotechnology | Director/Board Member | |
Epilepsy Foundation
 Epilepsy Foundation Miscellaneous Commercial ServicesCommercial Services Epilepsy Foundation provides welfare services. It offers therapies to stop seizures, wellness institute and legal issue services. The company was founded in 1967 and is headquartered in Landover, MD. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| All India Institute of Medical Sciences | College/University | Doctorate Degree | |
| Sarcoma Alliance for Research through Collaboration | Director/Board Member | ||
| AXCA HEALPAR | Biotechnology | Corporate Officer/Principal Director of Finance/CFO Director of Finance/CFO | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin | |
| CRISPR THERAPEUTICS AG | Biotechnology | Chairman Director/Board Member Chief Executive Officer | |
ClarVista Medical, Inc.
 ClarVista Medical, Inc. Medical SpecialtiesHealth Technology ClarVista Medical, Inc. operates as a medical device company which focuses on the novel solutions in ophthalmology. It develops the harmoni modular intra-ocular lens systems to optimize vision in the setting of cataract surgery. The company was founded by Paul McLean and Robert E. Atkinson in 2012 and is headquartered in Aliso Viejo, CA. | Medical Specialties | Director/Board Member | |
| University of Pennsylvania Medical Center | College/University | Doctorate Degree | |
Cardionomic, Inc.
 Cardionomic, Inc. Medical/Nursing ServicesHealth Services Cardionomic, Inc. engages in the development of medical devices. The company was founded in 2011 and is headquartered in New Brighton, MN. | Medical/Nursing Services | Director/Board Member | |
| ARCELLX, INC. | Biotechnology | Director/Board Member | |
| TCR2 THERAPEUTICS INC. | Pharmaceuticals: Major | Chief Executive Officer | |
| STOKE THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| Versant Ventures (Switzerland) GmbH | Investment Managers | Private Equity Investor Private Equity Analyst | |
| OYSR POIN | Pharmaceuticals: Major | Chairman | |
| NKARTA, INC. | Biotechnology | Chairman | |
New Enterprise Associates LLC
 New Enterprise Associates LLC Investment ManagersFinance New Enterprise Associates LLC is an alternative investment manager. The private company is based in Timonium, MD. The company was founded in 1978 by Chuck Newhall, C. Richard Kramlich. | Investment Managers | Corporate Officer/Principal | |
Korro Bio, Inc.
 Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member | |
Monte Rosa Therapeutics AG
 Monte Rosa Therapeutics AG Pharmaceuticals: MajorHealth Technology Monte Rosa Therapeutics AG develops, manufactures and distributes cancer drugs that modulate protein degradation pathways. The company was founded in 2018 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Chairman Director/Board Member Corporate Officer/Principal | |
Bright Peak Therapeutics AG
 Bright Peak Therapeutics AG BiotechnologyHealth Technology Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member Corporate Officer/Principal | |
858 Therapeutics, Inc.
 858 Therapeutics, Inc. BiotechnologyHealth Technology 858 Therapeutics, Inc. operates as a pharmaceutical company. The company was founded in 2019 and is headquartered in San Diego, CA. | Biotechnology | Director/Board Member Director/Board Member | |
| MONTE ROSA THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| NUVATION BIO INC. | Biotechnology | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Stablix, Inc.
 Stablix, Inc. Miscellaneous Commercial ServicesCommercial Services Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022. | Miscellaneous Commercial Services | Director/Board Member | |
Tune Therapeutics, Inc.
 Tune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tune Therapeutics, Inc. is a genetic medicine company based in Durham, NC. Tune Therapeutics is pioneering a new therapeutic modality with its versatile and powerful tempo epigenomic control platform. The platform has the potential to fine-tune any gene network and unlock the full power and potential of regenerative medicine. The company is driving through an inflection point in the history of genetic medicine by addressing thousands of common and complex diseases for which no curative treatment is available. Tune Therapeutics pioneers next-generation genetic therapies by exploring epigenomic control for discovering novel targets that are inaccessible to other approaches. The company was founded in 2020 by Fyodor Urnov, Akira Matsuno, Charles A. Gersbach. The CEO is Matt Kane. | Pharmaceuticals: Major | Director/Board Member | |
| FirstLight Bio, Inc. | Director/Board Member | ||
SpyGlass Pharma Inc
 SpyGlass Pharma Inc Miscellaneous Commercial ServicesCommercial Services Spyglass Ophthalmics, Inc. develops products for vision and eye care. The company was founded by Malik Y. Kahook and Glenn Sussman and is headquartered in Mission Viejo, CA. | Miscellaneous Commercial Services | Director/Board Member | |
Launchpad Therapeutics, Inc.
 Launchpad Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Launchpad Therapeutics, Inc. develops novel therapeutics. | Miscellaneous Commercial Services | Director/Board Member President | |
GHO Capital Partners LLP
 GHO Capital Partners LLP Investment ManagersFinance GHO Capital Partners LLP (GHO Capital Partners) is a private equity firm founded in 2014 by Mireille G. Gillings, Dennis B. Gillings, Alan Browning MacKay, Michael Irvine Mortimer and Andrea Ponti. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor | |
| ADAPTIMMUNE THERAPEUTICS PLC | Biotechnology | Director/Board Member Director/Board Member |
Statistics
International
| United States | 36 |
| Switzerland | 7 |
| United Kingdom | 6 |
| Canada | 2 |
| India | 2 |
Sectoral
| Health Technology | 30 |
| Consumer Services | 8 |
| Commercial Services | 6 |
| Finance | 6 |
| Health Services | 2 |
Operational
| Director/Board Member | 230 |
| Corporate Officer/Principal | 100 |
| Independent Dir/Board Member | 92 |
| Chairman | 68 |
| Undergraduate Degree | 23 |
Most connected contacts
| Insiders | |
|---|---|
| Richard Berman | 61 |
| Robert Alexander Ingram | 43 |
| Bradley Bolzon | 41 |
| Kapil Dhingra | 39 |
| Ali Behbahani | 34 |
| Wendy Dixon | 25 |
| H. Philip Goodeve | 21 |
| Garry Menzel | 19 |
| Alexander Mayweg | 18 |
| Thilo Schroeder | 18 |
| Rachel Humphrey | 17 |
| Raj Shah | 16 |
| Douglas A. Hamilton | 16 |
| Patrick T. Mooney | 15 |
| Mark Velleca | 13 |
- Stock Market
- Insiders
- Elizabeth Buck
- Company connections
